What BPC-157 is
BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid sequence (GEPPPGKPADDAGLV) derived from a partial sequence of body protection compound, a protein identified in human gastric juice. It was first characterized in the 1990s by Predrag Sikirić and colleagues at the University of Zagreb, whose group has produced the majority of the published work on it since.
It's notably stable in gastric-acid-equivalent conditions, which is unusual for a peptide of this length and is one reason it has been studied via multiple routes of administration in animal models.
No specific endogenous receptor for BPC-157 has been identified. Proposed mechanisms in the literature center on downstream modulation of growth factor expression, nitric oxide signaling, and angiogenic pathways rather than a single-target interaction — a profile sometimes described as pleiotropic. This absence of an identified receptor is a genuine open question in the mechanistic literature, not a settled finding.
Tendon and ligament models
This is where the musculoskeletal literature is most concentrated.
Rat Achilles tendon transection. Staresinic and colleagues (Journal of Orthopaedic Research, 2003; PMID 14554208) used complete transection of the rat Achilles tendon and reported accelerated functional and histological recovery in treated animals, alongside in vitro stimulation of tendocyte outgrowth.
Tendon-to-bone reattachment. Krivić and colleagues (PMID 16583442) examined Achilles detachment in rats — a model in which tendon-to-bone healing does not occur spontaneously. The study reported improvement across functional (Achilles functional index), biomechanical (load to failure, stiffness, Young's modulus), and histological endpoints including collagen fiber organization and collagen type I content. The same work reported that BPC-157 reduced the healing impairment produced by concurrent 6α-methylprednisolone.
Ligament healing. Cerovecki and colleagues (Journal of Orthopaedic Research, 2010;28:1155–1161) reported improved healing in a rat medial collateral ligament model.
In vitro mechanism. Chang and colleagues (Molecules, 2014;19:19066–19077) treated rat Achilles tendon fibroblasts and identified growth hormone receptor as among the most upregulated genes by cDNA microarray, with dose- and time-dependent increases confirmed at both mRNA and protein level.
Angiogenesis. Brcić and colleagues (Journal of Physiology and Pharmacology, 2009;60 Suppl 7:191–196) examined angiogenic modulation in muscle and tendon healing models.
Gastrointestinal models
The gastroprotective findings are the most frequently replicated in the literature — unsurprising given the peptide's origin in gastric juice. Published rodent work covers NSAID-induced gastric lesions, ethanol-induced mucosal damage, and several colitis models. BPC-157 has also appeared in the clinical-trial literature under the designations PL 14736 and PLD-116 in an inflammatory bowel disease context.
Muscle and other tissue models
Published rodent work extends to muscle-to-bone reattachment after quadriceps detachment, myotendinous junction injury, skin wound closure, and fracture healing models. Neurological work in rodents has examined protection against dopaminergic neurotoxins.
The limitations — read this section carefully
Anyone using this literature to design an experiment needs to weigh the following.
1. Publication concentration. A large majority of BPC-157 papers originate from a single research group. That group has published extensively and rigorously, but independent replication across labs is limited relative to the volume of published findings. Concentrated authorship is a recognized source of systematic bias, and it applies here.
2. The evidence is preclinical. The overwhelming majority of the data comes from rat and mouse models and in vitro systems. There are no published Phase II or Phase III randomized controlled trials establishing efficacy in humans for the musculoskeletal indications the preclinical work addresses.
3. No FDA approval. BPC-157 is not an approved drug in the United States for any indication. It is not a dietary supplement. A 2025 systematic review in the orthopaedic sports medicine literature (PMID 40756949) noted the absence of FDA approval alongside increasing off-label interest — a gap between evidence and use that is itself worth noting.
4. Prohibited in competitive sport. BPC-157 appears on the World Anti-Doping Agency Prohibited List under S0 (Unapproved Substances).
5. Sourcing variability. Material sold under this name varies substantially in purity, identity, and net peptide content. Preclinical results are not reproducible with unverified material, and a meaningful fraction of published irreproducibility in peptide research traces to input material rather than experimental design. Lot-specific HPLC and mass spectrometry documentation is the minimum — see our guide to reading a certificate of analysis.
6. Model translation. Rodent healing kinetics, tissue loading, and scale differ from human physiology in ways that make direct extrapolation unsound. This is a general limitation of preclinical repair research, not specific to this compound.
Practical handling notes for laboratory use
BPC-157 is supplied as a lyophilized powder and is generally water-soluble. Standard practice applies: equilibrate the sealed vial to room temperature before opening, reconstitute gently, aliquot for single use, and store protected from light. Our reconstitution and storage guide covers the full protocol, and the category background sits in our overview of research peptides.
Verify identity by mass spectrometry against the theoretical mass for the sequence before use in any quantitative work. Handling and distribution of this material sits under the framework described in our RUO compliance guide.
References
- 1Staresinic M, et al. J Orthop Res. 2003. PMID 14554208
- 2Krivic A, et al. PMID 16583442
- 3Cerovecki T, et al. J Orthop Res. 2010;28:1155–1161
- 4Chang CH, Tsai WC, Hsu YH, Pang JH. Molecules. 2014;19:19066–19077
- 5Brcic L, et al. J Physiol Pharmacol. 2009;60(Suppl 7):191–196
- 6Systematic review, orthopaedic sports medicine perspective. PMID 40756949
All references should be verified against PubMed prior to citation.
Frequently asked questions
What is BPC-157?
A synthetic 15-amino-acid peptide derived from a partial sequence of body protection compound, a protein identified in human gastric juice. It is supplied for laboratory research use only.
What does the preclinical BPC-157 research cover?
Published animal and in vitro studies span tendon and ligament healing models, gastrointestinal lesion models, muscle and bone reattachment, wound healing, and some neurological paradigms — predominantly in rats and mice.
Are there human clinical trials of BPC-157?
There is limited early clinical trial history under the designations PL 14736 and PLD-116 in a gastrointestinal context. There are no published Phase II or Phase III randomized controlled trials supporting the musculoskeletal applications examined in the preclinical literature.
Is BPC-157 FDA approved?
No. BPC-157 is not approved by the FDA for any human or veterinary use and is not a dietary supplement. It is supplied for laboratory research use only.
Is BPC-157 permitted in competitive sport?
No. It appears on the WADA Prohibited List under S0 (Unapproved Substances).
What is the main limitation of the BPC-157 evidence base?
That it is overwhelmingly preclinical and heavily concentrated in publications from a single research group, with limited independent replication and no large human efficacy trials.